Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin
The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
This study presents the long-term safety data from AFCAPS/TexCAPS, the first primary prevention trial to demonstrate that men and women with average levels of low-density lipoprotein cholesterol (LDL-C) and below average levels of high-density lipoprotein cholesterol (HDL-C) can significantly benefit from long-term treatment to lower LDL-C; lovastatin 20 to 40 mg/day reduced the risk of a first acute major coronary event (fatal or nonfatal myocardial infarction, unstable angina, or sudden death) by 37% (p = 0.00008). This double-blind randomized, placebo-controlled trial, in 6,605 generally healthy middle-aged and older men and women, had prespecified end point and cancer analyses. All analyses were intention-to-treat. Safety monitoring included history, physical examination, and laboratory studies (including hepatic transaminases and creatine phosphokinase [CPK]). All participants, even those who discontinued treatment, were contacted annually for vital status, cardiovascular events, and cancer history. After an average of 5.2 years of follow-up, there were 157 deaths (80 receiving lovastatin and 77 receiving placebo; relative risk [RR] 1.04; 95% confidence interval [CI] 0.76 to 1.42; p = 0.82); of which 115 were noncardiovascular (RR 1.21; CI 0.84 to 1.74; p = 0.31), and of these, 82 were due to cancer (RR 1.41; CI 0.91 to 2.19; p = 0.13). There were no significant differences between treatment groups in overall cancer rates, discontinuations for noncardiovascular adverse experiences, or clinically important elevations of hepatic transaminases or CPK. Among those who used cytochrome P450 isoform (CYP3A4) inhibitors, there were no treatment group differences in the frequency of clinically important muscle-related adverse events. Treatment with lovastatin 20 to 40 mg daily for primary prevention of coronary heart disease was well tolerated and reduced the risk of first acute coronary events without increasing the risk of either noncardiovascular mortality or cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vast majority of cases, SAMS are not accompanied by marked CK elevation.24,29”
Citations
Cites
Statistical Abstract of the United States
(2005) · Encyclopedia of Statistical Sciences · doi:10.1002/0471667196.ess2527 · Cited by 8,785
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Bradford, R. H. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400010067008 · Cited by 372
Research works printed but not linked: 1
- 1994, Randomized study of cholesterol lowering in 4444 participants with coronary heart disease, Lancet, 344, 1383
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Metadata
- Authors
- Downs, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., & Gotto, A. M.
- Affiliations
- Wilford Hall Ambulatory Surgical Center (US)
- University of North Texas (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of North Texas Health Science Center (US)
- Cornell University (US)
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 87
- Issue
- 9
- Pages
- 1074-1079
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2054688528
- Cited by
- 138
- References
- 22
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 6 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 4
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- lovastatin, primary prevention, coronary artery disease, LDL cholesterol lowering, statin safety, long-term tolerability, cancer risk, non-cardiovascular mortality, CYP3A4 inhibitors, hepatic transaminases, creatine kinase
- MeSH terms
- Aged, Analysis of Variance, Anticholesteremic Agents, Coronary Artery Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Lovastatin, Male, Middle Aged, Military Personnel, Primary Prevention, Risk Factors, Texas, Proportional Hazards Models, Treatment Outcome, Diet, Fat-Restricted
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin. https://app.cochat.ai/papers/10.1016/s0002-9149(01)01464-3
- The paper
- Downs, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., & Gotto, A. M. (2001). Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin. The American Journal of Cardiology. https://doi.org/10.1016/s0002-9149(01)01464-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.